Please assess the completion status of the following clinical trial:

Trial Title: Ranitidin Versus Omeprazole in Patients Taking Clopidogrel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years old~* Coronary artery disease, defined as previous myocardial infarction and/or coronary angioplasty and/or CABG surgery and/or coronariography showing obstruction of at least 50 % in one of major epicardial vessels~* Treatment with Acetylsalicylic Acid (ASA) 100 mg/day~Exclusion Criteria:~* Use on the last 7 days of any other antiplatelet drug beside ASA or oral anticoagulant~* Previous utilization of PPI or ranitidine in the last 7 days before randomization~* Any active bleeding~* Pregnancy or woman of childbearing age without contraceptive method~* Hemoglobin \< 10 g/dL or hematocrit \< 30 %, hematocrit \> 50 %, platelets \< 100.000/mm3 or \> 500.000/mm3; creatinin clearance \< 50 ml/minute~* Percutaneous coronary intervention (PCI) on the last 30 days before randomization (or PCI on the last year when drug-eluted stents are used); CABG surgery on the last 90 days; acute coronary syndrome on the last 60 days~* Active malignant neoplasm~* Active peptic ulcer disease on the last 60 days or upper gastrointestinal bleeding any time in life~* Known allergy to the drugs clopidogrel, ranitidine or omeprazole~* Refuse to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- omeprazole (Type: EXPERIMENTAL): Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
- ranitidine (Type: EXPERIMENTAL): Ranitidine 150 mg (oral route) twice a day will be given to the subjects for one week.

Based on this trial design, predict the completion outcome and termination type (if applicable).